MEDI-8852
- Generic Name
- MEDI-8852
Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Type A Influenza.
Phase 2
Withdrawn
- Conditions
- Influenza - Type A Strains
- Interventions
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2019-03-14
- Lead Sponsor
- MedImmune LLC
- Registration Number
- NCT03028909
A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 126
- Registration Number
- NCT02603952
- Locations
- 🇿🇦
Research Site, Welkom, South Africa
Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Adults
- First Posted Date
- 2015-01-30
- Last Posted Date
- 2015-07-13
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 94
- Registration Number
- NCT02350751
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath